TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Thoratec Corporation (NASDAQ:THOR) Investor Lawsuit Over Alleged Wrongdoing In Proposed Takeover By St. Jude Medical

  • If you purchased shares of Thoratec Corporation (NASDAQ:THOR), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Thoratec Corporation
Security
NASDAQ: THOR

Case Name
Thoratec Deal Case 08/10/2015
Type of Lawsuit
Mergers and Acquisition
You must register or login to receive notifications.

Click here to subscribe to Thoratec Corporation.
Summary

August 11, 2015 (Shareholders Foundation) - An investor who currently holds shares of Thoratec Corporation (NASDAQ:THOR), filed a lawsuit in effort to halt the proposed takeover of Thoratec Corporation by St. Jude Medical for $63.50 per share.

The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ:THOR stockholders by agreeing to sell Thoratec Corporation too cheaply via an unfair process to St. Jude Medical.

On July 22, 2015, St. Jude Medical (NYSE:STJ) and Thoratec Corporation (NASDAQ:THOR) announced that the Boards of Directors of both companies have unanimously approved an agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash transaction valued at approximately $3.4 billion, net of cash acquired.

However, the plaintiff claims that the proposed consideration NASDAQ:THOR shareholders will receive is grossly inadequate and undervalues Thoratec Corporation. The plaintiff alleges that the $63.50-offer does not take into account Thorate’s recent growth through strategic acquisitions and novel product developments. In addition, the plaintiff claims that the process is also unfair to NASDAQ:THOR stockholders.